<?xml version="1.0" encoding="UTF-8"?>
<p>IP2-ATLANTA is an unblinded, randomised, multicentre, interventional three-arm study with an active comparator arm incorporating standard of care (SOC) (
 <xref ref-type="fig" rid="F1">figure 1</xref>). Study participants will be randomised to: Control arm (standard of care); Intervention arm 1 (MIAT±pelvic lymph node dissection (PLND)) or Intervention arm 2 (prostate external beam radiotherapy (EBRT)±PLNRT OR cytoreductive radical prostatectomy (CRP)±PLND). Systemic therapy in all arms includes ADT±docetaxel, abiraterone acetate, enzalutamide, apalutamide, as appropriate. Men with low-burden disease in intervention arms are eligible for MDT in the form of SABR or surgery (
 <xref ref-type="fig" rid="F1">figure 1</xref>).
</p>
